Neurology · Movement DisordersRegulatory Approvalregulatorymid-term

FDA Approval Status Update for Deutetrabenazine by Aurobindo Pharma

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Aurobindo Pharma25 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/12/2026, 12:33:58 AM

Assessment confidence: 62% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's review of Aurobindo Pharma's application for deutetrabenazine is significant as it marks the company's entry into the competitive movement disorders market. This could impact pricing strategies and market dynamics for existing products in this therapeutic area. Regulatory context from FDA (FDA AP — DEUTETRABENAZINE (SUPPL)) supports the near-term read. Assessment grounded in 18 ranked evidence items (6 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of Aurobindo's entry on market dynamics and pricing strategies for existing products. The strongest clinical anchor is Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease (ClinicalTrials.gov), moderate corpus alignment. In Neurology · Movement Disorders, 6 regulatory and 2 competitive items passed relevance filtering for Aurobindo Pharma.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts BLA for Langlara by Sunshine Lake Pharma (Humanexa Signals) — moderate corpus alignment. Secondary pressure from FDA Approves Isatuximab-irfc Subcutaneous Injection for Multiple Myeloma. This submission indicates Aurobindo's entry into the market for deutetrabenazine, potentially increasing competition in the movement disorders space.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — DEUTETRABENAZINE (SUPPL) (FDA). Entity match (aurobindo pharma); Regulatory pathway relevance (nda). The standard review process indicates that while approval is not guaranteed, it is a significant step that could influence future regulatory strategies for similar products.

Key Risks

Elevated medium regulatory exposure for Aurobindo Pharma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Aurobindo's entry may lead to increased competition, potentially affecting market share and pricing for current players in the movement disorders segment.
Upside for Aurobindo Pharma may improve if Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the impact of Aurobindo's entry on market dynamics and pricing strategies for existing products.

What Would Change This Assessment

This becomes more urgent if Monitor the progress of the FDA review and any subsequent market entry timelines.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — DEUTETRABENAZINE (SUPPL)
FDAhigh relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ALFUZOSIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — FINASTERIDE (SUPPL)
FDAhigh relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ACYCLOVIR (SUPPL)
FDAhigh relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson's Disease Patients
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Influence of Maternal Age, Employment Status, and Parenthood Status on Children's Cognitive Development
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Collection of Pharmacokinetic Samples From People With Unanticipated Response, Significant Toxicity or Concern of Future Toxicity
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts BLA for Langlara by Sunshine Lake Pharma
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves Isatuximab-irfc Subcutaneous Injection for Multiple Myeloma
Humanexa Signalsmedium relevance
Moderate corpus alignment

Insect-based models in pharmaceutical ecotoxicology: a bibliometric and narrative review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
RNA polymerase II phosphorylation dynamics: from molecular mechanisms to human disease.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Wedelactone-loaded exosomes for sepsis-induced liver injury: a novel therapeutic strategy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Aurobindo Pharma
deutetrabenazine

Commercial impact

medium

Aurobindo's entry may lead to increased competition, potentially affecting market share and pricing for current players in the movement disorders segment.

Regulatory impact

medium

The standard review process indicates that while approval is not guaranteed, it is a significant step that could influence future regulatory strategies for similar products.

What to watch

Monitor the progress of the FDA review and any subsequent market entry timelines.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.